IFNL3 and chronic hepatitis: The efficacy of triple therapy in therapy-naïve and relapser patients with HCV-1 chronic hepatitis was greater than that of dual therapy regardless of the IL-28B genotype, the severity of liver fibrosis, HCV sub-genotype, and HCV load at the baseline, thus indicating that these factors do not affect the different efficacy between dual and triple therapy in these patients.